




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |   |   |
|---|---|---|
| (51) International Patent Classification <sup>5</sup> :<br><br>C12Q 1/68  | A1  | (11) International Publication Number: <b>WO 93/04200</b><br><br>(43) International Publication Date: 4 March 1993 (04.03.93) |
| (21) International Application Number: PCT/US92/06701<br>(22) International Filing Date: 10 August 1992 (10.08.92)<br>(30) Priority data:<br>743,606                      12 August 1991 (12.08.91)        US<br>(71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).<br>(72) Inventors: McGUIRE, William, L. ; 28433 Dalcin, San Antonio, TX 78260 (US). FUQUA, Suzanne, A. ; 2643 Inwood View, San Antonio, TX 78248 (US).<br>(74) Agent: MAYFIELD, Denise, L.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US). | (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).<br><br>Published<br>With international search report. |   |

(54) Title: METHODS AND COMPOSITIONS FOR THE DETECTION AND PREDICTION OF BREAST CANCER



## (57) Abstract

A nucleic acid *Hind*III RFLP characteristic of human breast cancer or susceptibility to human breast cancer is presented. Restriction fragment length polymorphisms (RFLPs) are detectable using a restriction endonuclease capable of providing *Hind*I-DNA restriction fragments. The most frequent *Hind*III allelic profile of a person with breast cancer or susceptible to breast cancer is determined to be H2/H2 homozygous or to be absent an H1 allele. The *Hind*III RFLP may be used to detect or predict persons at risk of (or susceptible to) breast cancer through analysis of a wide variety of tissues, including breast tissues, tissue adjacent to a breast tumor, tissue and blood cells. A nucleic acid segment, particularly of 1.23 kb or less, and suitable for use as a probe for identifying specific DNA regions of the RFLP polymorphism, is also disclosed and constitutes part of a diagnostics kit for the identification of patients with or at risk of breast cancer.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | FI | Finland                               | MN | Mongolia                 |
| AU | Australia                | FR | France                                | MR | Mauritania               |
| BB | Barbados                 | GA | Gabon                                 | MW | Malawi                   |
| BE | Belgium                  | GB | United Kingdom                        | NL | Netherlands              |
| BF | Burkina Faso             | GN | Guinea                                | NO | Norway                   |
| BG | Bulgaria                 | GR | Greece                                | NZ | New Zealand              |
| BJ | Benin                    | HU | Hungary                               | PL | Poland                   |
| BR | Brazil                   | IE | Ireland                               | PT | Portugal                 |
| CA | Canada                   | IT | Italy                                 | RO | Romania                  |
| CF | Central African Republic | JP | Japan                                 | RU | Russian Federation       |
| CG | Congo                    | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CH | Switzerland              | KR | Republic of Korea                     | SE | Sweden                   |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovak Republic          |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CS | Czechoslovakia           | LU | Luxembourg                            | SU | Soviet Union             |
| CZ | Czech Republic           | MC | Monaco                                | TD | Chad                     |
| DE | Germany                  | MG | Madagascar                            | TG | Togo                     |
| DK | Denmark                  | MI | Mali                                  | UA | Ukraine                  |
| ES | Spain                    |    |                                       | US | United States of America |

-1-

DESCRIPTION  
METHODS AND COMPOSITIONS FOR THE  
DETECTION AND PREDICTION OF BREAST CANCER

5

The United States Government may own rights in the present invention as research relevant to the development thereof was supported by National Institutes of Health (NIAID) Grant No. CA30195

10

BACKGROUND OF THE INVENTION

1. Field of the Invention

15

The present invention relates to methods for detecting, as well as predicting, persons at risk of developing breast cancer. More specifically, the present invention provides a method for characterizing a person as having breast cancer, or as at risk of developing breast cancer, on the basis of a particular allelic profile manifest in persons with a particular nucleic acid genetic abnormality. Such a genetic abnormality is detectable in a *HindIII* RFLP. The RFLP of the present invention is further defined as being in close proximity or within to the progesterone receptor gene, most specifically on the long arm of the chromosome 11.

20

25

30

35

In particular embodiments, the RFLP of the present invention is identified in *HindIII* enzyme generated DNA fragments employing particularly defined nucleic acid segments suitable for use as DNA probes. The inventors have discovered that a certain percentage of persons whom have breast cancer or whom are characterized as "at risk" of developing this condition are found to be homozygous for the H2 allele (H2/H2) or are absent the H1 allele. Thus, it is either the presence of both H2 alleles, or the absence of the H1 allele, that serves to identify

-2-

persons susceptible to breast cancer or persons who already have breast cancer. As such, the present invention also relates to the field of diagnostic tests and kits for breast cancer.

5

## 2. Description of the Related Art

The steroid hormones, estradiol and progesterone, have profound effects upon the differentiation and proliferation of a number of target tissues, such as uterus and breast, and their actions are mediated by specific, low abundance intracellular receptors. The receptors for these hormones are known to modulate the transcription of specific genes, and are members of a superfamily of ligand-inducible enhancer factors<sup>1</sup>.

The PgR, (progesterone receptor) in addition to being a gene regulator, is itself regulated by estrogen through the estrogen receptor (ER), thereby adding to the complexity of hormonal regulation in target tissues. PgR content has been found useful for predicting disease-free survival in human breast cancer, and is routinely measured in the clinical setting<sup>2,3</sup>. Several groups have now cloned the gene for PgRs from several species, and have demonstrated that human PgR is encoded by a single gene residing on chromosome 11<sup>4</sup>. This localization is characterized by frequent alterations and loss of chromosome 11 sequences in human breast cancer<sup>5-11</sup>.

Chromosomal alterations and/or deletions are aberrations which have been proposed as mechanisms underlying oncogenesis. Indeed, amplification of specific oncogenes, such as c-erbB-2 and int-2, or alterations to c-H-ras-1, c-myc, and c-myb, may all contribute to either the genesis or the progression of human breast cancer<sup>12-17</sup>.

-3-

Progesterone and breast cancer have been linked since the concept of hormone-dependent cancers was first elaborated<sup>27-28</sup>. In regard to biological factors, the literature reveals a wide range of potential physiological and biochemical factors as well as oncogene linked mechanisms, which result in the development of breast cancer.

Restriction fragment length polymorphism (RFLP) offers a powerful molecular genetic tool for the direct analysis of the human genome to determine elements that signal predisposition to genetic diseases<sup>29</sup>. Thus, such a technique permits the detection of variation in the human genome, and for the construction of genetic linkage maps. The technique of RFLP has been used to obtain information necessary to create genetic probes (isolated from chromosome-specific phage libraries) which contain a specific DNA portion of human DNA of interest.<sup>30</sup> With this tool in hand, the analysis of human gene segments is possible.

For example, restriction fragment analysis has been employed to examine relatively large segments of the human PgR gene which resides on chromosome 11.<sup>8</sup> The absence of PgR in a breast tumor could be due to a molecular alteration specifically in the PgR gene, or a consequence of defective regulation of the PgR gene by ER, or even to the concentration of steroid ligands themselves. These theories are supported by observations of others which report that PgR gene expression is under the dual control of both estrogen and progesterone<sup>18,19</sup>. However, a specific method for genetically identifying or predicting patients at genetic risk for developing breast cancer employing a part specific RFLP and specific patient allelic profile has not yet been reported.

-4-

The definition of specific gene abnormality in the breast tissue of a patient would provide an important advance in the art of breast cancer diagnostic tests. Even more importantly, a method which detects a genetic abnormality specific for breast cancer would be of potential value in objectively identifying individuals who are genetically predisposed to the development of breast cancer.

The elucidation of a specifically defined polymorphism in the DNA of a patient which was characteristic of breast cancer and conditions of occult breast cancer, would provide a valuable genetic marker for detecting as well as predicting the predisposition of a person for breast cancer.

#### SUMMARY OF THE INVENTION

The present invention provides a powerful specific method for the identification of particularly defined allelic polymorphisms useful in the diagnosis of human breast cancer. The present invention also provides methods whereby persons at risk for developing breast cancer may also be identified, i.e. in the diagnosis of occult breast cancer. These methods may be used in the analysis of nucleic acid obtained from tumorous tissue, such as from a breast tumor biopsy, as well as from non-tumorous tissues, such as blood, tissues adjacent a malignant breast tumor mass, skin, hair, buccal smear and thymus tissue.

The present inventors have discovered that the technique of RFLP may be employed in a method to detect the presence of a specific polymorphism(s) which indicates the presence of or a predisposition to breast cancer. This polymorphism may potentially be present in

-5-

the DNA found in cells of many tissue types. It is postulated that the presence of the specific polymorphism described herein may also be involved in the mechanism whereby a particular oncogene(s) is activated during the malignant disease process, or in the alternative, be involved in the suppression of a tumor suppressor gene.

The present inventors have discerned the existence of particular chromosome alterations in DNA obtained from breast tumor tissue. This particular RFLP is identifiable using a nucleic acid segment having a sequence defined in Figure 1. Test sample nucleic acid obtained from a patient which is found to include sequences hybridizable to a sequence or part of a sequence which corresponds to the *HindIII* RFLP of breast cancer, as defined in Figure 1, or a fragment thereof, are identified as positive for breast cancer.

The particular *HindIII* RFLP for human breast cancer employed in the disclosed methods and kits are further defined as being located in close proximity to or within the progesterone receptor (PgR) gene. The PgR gene is located at chromosome 11.

In one embodiment of the present invention, a method employing a specific nucleic acid segment characteristic of human breast cancer is defined. The particular nucleic acid segment thus constitutes a genetic marker detectable as a RFLP (restriction fragment length polymorphism) comprising a *HindIII* polymorphism. The described genetic marker of the present invention includes a *HindIII* polymorphism further defined by a particular allelic profile, being either an absence of an H1 allele or an H2/H2 homozygous allelic profile condition. Thus, persons having an H1/H2 allelic profile or the absence of an H2 allele (i.e., an H1/H1 allelic profile) would be identifiable as not having the

-6-

particular *Hind*III polymorphism characteristic of human breast cancer or susceptibility thereto, according to the claimed method.

5           In preferred embodiments, the RFLP of the present invention may be defined in terms of hybridization probe sequences that will bind to, and therefore identify, the RFLP. In one aspect, therefore, the H1 or H2 is defined as a nucleic acid segment that will hybridize  
10 specifically with a nucleic acid segment prepared with sequence characteristics of an H1 or H2 polymorphism. Nucleic acid segments of about 1.23 kb or less are preferred because of enhanced specificity and decreased monetary expense for the production of a shorter nucleic  
15 acid segment. More specifically, it is generally recognized that the longer a particular "identifying" (i.e. "probe") nucleic acid sequence is, the greater the possibility that hybridization will occur between parts of the "identifying" sequence unrelated to the particular  
20 genetic disorder of interest. Thus, by employing smaller nucleic acid segments as an "identifying" nucleic acid sequence, the inventors provide a diagnostic test having enhanced specificity for human breast cancer and having a decreased probability of reporting a "false positive"  
25 result for breast cancer or susceptibility thereto. An example of such a nucleic acid segment is the 1.23 kb nucleic acid sequence set forth in Figure 1. Even more preferred, however, will be shorter sequences that maintain specificity for both the H1 and H2 alleles. For  
30 example, such may be defined in the inventors prophetic 0.48 kb nucleic acid segment sequence set forth in figure 2.

35           In another embodiment of the present invention, a method for diagnosing breast cancer or susceptibility to breast cancer in a patient is provided. In a most preferred embodiment, the method comprises obtaining a



-7-

tissue or blood specimen from a patient, processing the specimen to obtain DNA, subjecting the DNA to a restriction enzyme capable of defining regions of a *HindIII* polymorphism, so as to provide DNA restriction fragments, and diagnosing a patient homozygous for the H2 allele or absent a H1 allele as having breast cancer or as being susceptible to breast cancer. More specifically, the DNA of the patient used in the described method is genomic DNA.

10

The DNA restriction fragments as prepared in the process of the claimed method are separated by length to provide isolated DNA restriction fragments. The isolated DNA restriction fragments so obtained are then most preferably probed to locate segments of a *HindIII* RFLP therein, said segments of the RFLP being hybridizable to a nucleic acid segment having an H1 or H2 allele. The inventors have found the *HindIII* RFLPs to reside at those patient DNA fragments which have a length of about 2.8 kb (H1 allele) and about 2.5 kb (H2 allele).

20

Even more specifically, the isolated DNA restriction fragments are probed with a nucleic acid segment suitable for use as a probe and having a sequence defined in Figure 1 or a fragment thereof. Even more preferably, a prophetic embodiment of the method employs a nucleic acid segment suitable for use as a probe and having a sequence as defined in Figure 2 or a fragment thereof.

25

In a particularly preferred embodiment of the claimed method, the DNA restriction fragments are separated by the process of electrophoresis. The inventors propose to discern smaller nucleic acid fragments which include even more narrowly defined nucleic acid sequences characteristic of the H1 and H2 allele. In such event, the nucleic acid fragments of a patient DNA sample need not first be separated by

30  
35

-8-

electrophoresis. Instead, the presence of the H1 and the H2 alleles would be determined, and the allelic profile of the patient discerned and classified as either characteristic of breast cancer or susceptibility thereto, or not. Thus, invariant PgR bands, which appear at 3.6, 4.7 and 9.0 kb on the Southern Blot of Figure 3, need not be considered.

Typically, probes employed for detection purposes will be labeled to provide for their ready detection following hybridization. Of course, radioactive labels such as  $^{32}\text{P}$  are generally the most sensitive for identification purposes, through, e.g., autoradiography. However, radioactive labels suffer from disadvantages due to the need for disposal of radioactive wastes and the short half-life of, e.g.,  $^{32}\text{P}$ . Therefore, it may be desirable to employ non-radioactive labels such as avidin/biotin or enzyme ligands such as alkaline phosphatase, horseradish peroxidase, etc., which may be detected through the use of colorimetric substrates.

While it is proposed that any of a variety of restriction enzymes may be used in the practice of the present invention, the restriction enzyme most particularly preferred is the *HindIII* restriction enzyme. A restriction enzyme capable of defining regions of a *HindIII* polymorphism may be used in conjunction with any and all of the described aspects of the present invention. Restriction enzymes found not to provide these requisites include *EcoRI* and *Pvu II*. In a most preferred embodiment of the claimed method, the restriction enzyme is *HindIII* restriction enzyme.

Turning now to a consideration of where the particular polymorphisms characteristic of breast cancer or susceptibility to breast cancer may be found, the present inventors have discovered that isolated DNA

-9-

restriction fragments obtained from the patient's DNA include the H1 allele to be located in a restriction fragment which has a length of about 2.8 kb. The H2 allele is to be found in a DNA restriction fragment which has a length of about 2.5 kb. The H1 allele or the H2 allele may be located according to the present methods by probing the isolated DNA restriction fragments with a nucleic acid segment having the sequence defined in Figure 1 or a fragment thereof. In one particularly preferred embodiment of the claimed method, the presence of an H2 allele or an H1 allele is identifiable in a DNA restriction fragment which hybridizes with a probe having a sequence defined in Figure 1, or a fragment thereof. In an even more particularly preferred prophetic embodiment of the claimed method, the presence of an H2 allele or an H1 allele may be identified in a DNA restriction fragment which hybridizes with a nucleic acid a sequence defined in Figure 2 or a fragment thereof.

A nucleic acid probe, preferably DNA, having a sequence as defined in Figure 1 may be prepared as an *AccI*/*Bam*HI generated fragment of a *PgR* cDNA. This particular embodiment of the probe is a 1.23 kb DNA fragment of the *PgR* cDNA.

In a more narrowly defined embodiment of the present invention, a method of detecting a *Hind*III RFLP in DNA is provided. In this method, the *Hind*III RFLP identifies a polymorphism characteristic of breast cancer or susceptibility thereto. The method comprises treating the DNA sample with a restriction enzyme capable of producing a DNA restriction fragment having a *Hind*III polymorphism, to produce DNA restriction fragments, probing the DNA restriction fragments with a nucleic acid segment capable of identifying a *Hind*III RFLP, and identifying a *Hind*III RFLP in a segment of the separated DNA restriction fragment which hybridizes with the

-10-

nucleic acid segment or a fragment thereof. In the described method, the polymorphism for breast cancer or susceptibility to breast cancer is a deletion of an H1 allele. Alternatively, the polymorphism for breast cancer or susceptibility to breast cancer discernible with the described method is a H2/H2 allelic profile. In still another embodiment of the claimed method, the particular allelic profile characteristic of breast cancer or susceptibility thereto is defined in an H1 P<sub>g</sub>R gene-free allelic profile or in an H2/H2 P<sub>g</sub>R gene allelic profile.

In still another embodiment of the present invention, a nucleic acid segment suitable for use as probe and capable of identifying a *Hind*III RFLP characteristic of human breast cancer or susceptibility thereto, is provided. The particular nucleic acid segment most preferably has 1.23 kb or less. The RFLP identifiable using the described nucleic acid segment in turn identifies an H2/H2 allelic condition or identifies the absence of an H1 allele in the allelic profile of the patient. In a most particularly preferred embodiment of the described nucleic acid segment, the nucleic acid segment has a sequence as defined in Figure 1 or a fragment thereof. In a prophetic embodiment of the nucleic acid segment, the segment is defined as having a sequence as defined in Figure 2, or a fragment thereof. Even more specifically this particular prophetic embodiment of the nucleic acid fragment has a length of about 0.48 kb.

In still further embodiments, the present invention is directed to kits for the prediction of breast cancer or breast cancer susceptibility in a patient. Kits of the present invention may be defined generally as including a hybridization probe capable of hybridizing to an H1 and H2 RFLP, wherein the probe is comprised in a

-11-

suitable container, such as a test tube or vial. The probe, whether it be an RNA or DNA segment, will also preferably be suitably aliquoted to render it ready for use with little or no pre-experimentation. Furthermore, the probe container will generally be packaged in a larger container or box for easy transportation, shipping, etc.

As discussed above, the nucleic acid probe will generally comprise a segment of about 1.23 kb or less that will nevertheless faithfully hybridize, and therefore identify, H1 and H2 alleles. Probes of this size are preferred in that they provide greater diagnostic specificity for the diagnosis of breast cancer and are economical to prepare. For this reason, nucleic acid probes that comprise the sequence of figure 1, or a fragment comprising a hybridizable portion of the sequence, will be particularly preferred. As used herein, the term "hybridizable" portion, is intended to refer to nucleic acid segments that are long enough to form specific hybrids with the H1 or H2 allele. In a prophetic embodiment, the nucleic acid probe comprises that sequence of Figure 2.

The size of the particular nucleic acid fragment employed in the described methods and kits is not to be limited to those of 1.23 kb or less in size.

Virtually any size nucleic acid segment or fragment thereof which includes a sequence characteristic of the *Hind* III RFLP described herein, and being hybridizable at least in part to the nucleic acid segment defined in Figure 1 may be employed in the described methods.

In still further embodiments, kits of the present invention will include a means for detecting hybridization between the probe and an H1 or H2 RFLP,

-12-

typically a label located either on the probe, or contained on a separate molecule that can be made to bind specifically to the probe (such as a second nucleic acid probe, and avidin/biotin binding pair, etc.). Preferred  
5 labels comprise an enzyme or radioactive label.

#### BRIEF DESCRIPTION OF THE DRAWINGS

10        *Figure 1:* SEQUENCE OF THE 1.23 kb NUCLEIC ACID SEGMENT SUITABLE FOR USE AS A PROBE USED TO IDENTIFY THE BREAST CANCER POLYMORPHISM PRESENT IN A *HindIII* RFLP.

15        *Figure 2:* SEQUENCE OF A 0.48 kb NUCLEIC ACID SEGMENT PROPOSED AS SUITABLE FOR USE AS A PROBE FOR THE PROPOSED IDENTIFICATION OF A BREAST CANCER POLYMORPHISM PRESENT IN A *HindIII* RFLP.

20        *Figure 3:* SOUTHERN HYBRIDIZATION ANALYSIS OF DNA FROM BREAST TUMORS, PLACENTAS AND NORMAL LYMPHOCYTES DIGESTED WITH *HindIII* AND PROBED WITH A NUCLEIC ACID SEGMENT OF 1.23 kb CLONE. The presented *HindIII* RFLP provides a representative Southern blot of genomic DNA from human placenta, breast tumor and peripheral blot  
25 lymphocytes digested with the restriction enzyme *HindIII*. The two *HindIII* alleles H1 (about 2.8 kb) and H2 (about 2.5-2.6 kb) are indicated. Invariant PgR bands are demonstrated at 9.0, 4.7, and 3.6 kb. The nucleic acid segment sequence of Figure 1 was employed as the probe.

30

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The presently described invention provides a specific genetic diagnostic test for the identification  
35 of patients who have breast cancer as well as those persons genetically susceptible to the development thereof. The trait observed by the inventors is highly

-13-

correlatable to the incidence of breast cancer in humans. This trait is identified in particularly described DNA restriction fragments of the patient DNA, which reveal either a homozygous condition for the H2 allele or an  
5 absence of the H1 allele. Thus, H1 could be or could be revealing a tumor suppressor gene.

The method for detecting the polymorphism diagnostic for breast cancer includes a nucleic acid segment which  
10 identifies the particular genetic abnormality in a *HindIII* restriction fragment prepared from a DNA patient sample. Accordingly, included in the present invention disclosure is information which may be used to prepare a wide variety of nucleic acid fragments having a number of  
15 potential utilities, such as the preparation of DNA and RNA sequences in PCR and hybridization studies as probes for *in vitro* detection, as well as other useful medical and biochemical applications related to the research, diagnosis and treatment of breast cancer.

20 The nucleic acid fragment for the purposes of the present invention is defined as a polymer of nucleic acids. More specifically, the nucleic acid segment is defined as a polymer of nucleic acids suitable for use as  
25 a probe and sufficient to provide for the hybridization of the nucleic acid segment with segments of a patient DNA sequence which include a complementary base sequence thereto, thus identifying a *HindIII* RFLP characteristic of breast cancer or a susceptibility to breast cancer.  
30 Measurement of any resulting double-helix formation (hybridization) provides a relative measurement of the relatedness between the patient DNA and the nucleic acid segment of the disclosed method.

35 Any tissue of the patient could be used to obtain a DNA sample suitable for analysis for the herein described genetic polymorphism. By way of example, such tissues

-14-

include both tumorous and nontumorous tissues. Tissues may also be used from a variety of tissue types, such as breast tissue, tissue adjacent breast tissue, blood cells, placental tissue, thymus tissue (thymus is a lymphocyte-rich tissue important in the production and maintenance of immune cells), skin, buccal smear and hair, among others. In the most preferred embodiments of the invention, the tissue type of choice for detection of a polymorphism characteristic of breast cancer or susceptibility thereto is breast tissue or blood cells. Blood cells such as granulocytes and lymphocytes are most particularly preferred.

Even though the invention has been described with a certain degree of particularity, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art in light of the foregoing disclosure. Accordingly, it is intended that all such alternatives, modifications and variations will fall within the spirit and the scope of the invention and be embraced by the defined claims.

The following examples are presented to describe preferred embodiments in utilities of the present invention, but should not be construed as limited the claims thereof.

#### Example 1

#### SYNTHESIS OF NUCLEIC ACID SEGMENT SEQUENCES FOR IDENTIFICATION OF HUMAN BREAST CANCER AND SUSCEPTIBILITY THERETO

The present example is provided to demonstrate several preferred methods by which the nucleic acid segments for identifying human breast cancer or susceptibility thereto may be prepared. However, any of a variety of methods other than the specific methods described herein, as well as a variety of variations from



-15-

the methods specifically described herein, may be used in the practice of the present invention.

5       The particular methods outlined herein are the synthesis of a cDNA clone, synthesis of a sequence using PCR, and synthesis of a sequence using a synthetic oligonucleotide synthesizer.

a.   *cDNA probe*

10       A DNA probe useful for the identification of a genetic polymorphism characteristic of breast cancer or susceptibility thereto in a particularly preferred embodiment is prepared using a nucleic acid sequence isolatable from a human PgR clone.

15       One particular PgR clone which was used in the preparation of a DNA probe suitable for use in the present invention was the human PgR clone hPR-56. This particular PgR clone, hPR-56, was isolated from a T47D-pCD library. The T47D-pCD library comprises a variety of clones containing the PgR gene sequence, and is described in Okayama et al. (1983).<sup>32</sup>

25       The particular hPR-56 clone consists of a 2.7 kb BamHI fragment of the human PgR, representing nucleotides 70-7835. The authenticity of the fragment sequence was confirmed by DNA sequence analysis.

30       The hPR-56 nucleic acid was digested with AccI to cleave the PgR sequence at nucleotide 1609, followed by digestion with BamHI, and a 1.23 kb AccI/BamHI fragment subcloned into pGEM (Promega, Inc.). This fragment was found by the present inventors to include a sequence useful in the identification of the genetic polymorphism  
35       for breast cancer and susceptibility to breast cancer.

-16-

b. *PCR amplified probe*

A synthetic oligonucleotide primer corresponding to nucleotides 1601 to 1620 of the human PgR cDNA plus an added EcoRI restriction site (5'-  
5 CGGAATTCTGCCGCAGGTCTACCCGCCC-3") and an antisense primer corresponding to nucleotides 2769 to 2788 plus an added HindIII restriction site (5'-  
GCAAGCTTAAGAGAAGGGTTTCACCATC-3') can be used to amplify by polymerase chain reaction (PCR) the 1.23 kb fragment  
10 from PgR cDNA.

Following PCR-amplification, the fragment was purified by agarose gel electrophoresis and labeled with <sup>32</sup>P-dNTP by random prime labeling using a commercially  
15 available kit (Boehringer Mannheim). However, these labeling components may also be prepared individually following standard procedures (Maniatus Molecular Biology Manual).

20 Alternatively, a prophetic nucleic acid segment having a length of about 1.23 kb may be prepared by PCR for use in conjunction with the described methods and kits. Specifically, a nucleic acid subfragment of the 1.23 kb PgR cDNA may be prepared using two  
25 oligonucleotide sense and antisense primer pairs chosen within the 1.23 kb cDNA. These internal PgR cDNA primers should consist of 20 to 30 oligonucleotides and contain approximately 50 to 65% C/G content. The distance  
30 between the two pairs may vary, but lengths between 100 to 200 may provide optimum ease of PCR amplification and specificity for detection of the HindIII RFLP. The primers can be used to PCR amplify PgR cDNA and the amplified fragment used as a probe as outlined in Example  
1. The labeled form of the fragment may be prepared  
35 using the radioisotopic label <sup>32</sup>P and used in a Southern analysis with genomic DNA from tissue specimens.

-17-

The PCR-generated probe may then also be used in hybridization reactions with the Southern nitrocellulose membranes as described in Example 2.

5     *c. Synthetic Oligonucleotide Synthesis of a probe*

10     The nucleic acid segment employed in the diagnostic methods and compositions herein may be synthesized as a 20 - 30 bp (base pair) synthetic oligonucleotide. As such, the oligonucleotides may be prepared via automated synthesizers, desalted, and used as probes. Most preferably, these oligonucleotides are to be labeled with a radioisotope, such as <sup>32</sup>P, using <sup>32</sup>P-dNTP's and T4 polynucleotide kinase. These labeled nucleotides may then be used in hybridization reactions with the Southern nitrocellulose membranes as described in Example 2.

**Example 2**

**HindIII RFLP of Breast Cancer in Human Tissue**

20

The present example is provided to demonstrate the first molecular genetic evidence, through the use of RFLP analysis, that an allelic polymorphism exists which is highly correlated to the occurrence and/or subsequent development of human breast cancer.

25

The present example is also provided to demonstrate the utility of employing the methods described herein for the detection of particular restriction fragment length polymorphisms (RFLP) indicative or predictive of human breast cancer, as identified in digested and isolated DNA restriction fragments of a patient's DNA.

30

The data herein indicate an identifiable polymorphism at the H1 and/or the H2 allele is present in a statistically significant number of tissues obtained from persons with breast cancer, compared to non-tumorous human tissues obtained from persons without breast

35

-18-

cancer. A total of 132 breast tumors were examined for the presence of the *Hind*III RFLP as an indicator of breast cancer, and established that an allelic profile of H2/H2 or an allelic profile absent the H1 allele was present in tissues obtained from patients diagnosed or later diagnosed to have breast cancer.

This *Hind*III RFLP was found by the inventors to not display typical Mendelian distribution in the breast tumors. In the ligand-binding assays conducted by the inventors, the *Hind*III RFLP did not correlate with the PgR expression. This suggests to the present inventors that the RFLP is not related to the heterogeneity of PgR expression seen in breast tumors.

The present examples provide an examination of the genomic status of the PgR gene in a total of 132 breast tumor biopsies using Southern hybridization analysis.

## MATERIALS AND METHODS

### *Cell Lines*

Six human breast cancer cell lines were used in the present studies, in these particular human breast cancer cell lines were:

T47D (ATCC No.HTB 133):  
ZR75 (ATCC No.CRL1500):  
MDA-231 (ATCC No.HTB26):  
MDA-468 (ATCC No.HTB132):  
MCF-7 (ATCC No.HTB22):  
MDA MB-330 (ATCC No.HTB127):

Cells were maintained as monolayer cultures in Eagles minimal essential medium with 10% fetal bovine serum. Also lines were shown to be free to microplasma contamination.

-19-

*HUMAN TISSUES*

Human placental tissues were obtained from a local medical center hospital. These tissues were collected immediately after parturition, trimmed free of excess connective tissue, rinsed in sterile phosphate buffered saline, frozen in liquid nitrogen, and stored at -70°C. Human breast tumor specimens, maintained at -70°C, consist of tissue remaining after routine estrogen and progesterone receptors assays and were collected from throughout the United States. Human peripheral blood leukocyte DNA was provided from local sources. Normal breasts and breast tumor pairs were obtained also from local sources and consisted of primary breast carcinoma specimens with adjacent benign breast tissue.

*DNA ANALYSIS*

High molecular weight genomic DNA was isolated on a Model 340A Nucleic Acid Extractor (Applied Biosystem, Inc., Foster City, CA) according to manufacturer's recommendations, and quantitated by diphenylamine assay<sup>25</sup>. Ten micrograms of DNA was digested with the appropriate restriction enzyme, separated by a electrophoresis on a 1% agarose gel, and transferred onto nitrocellulose by the method of Southern<sup>20</sup>. The nitrocellulose filters were hybridized to a <sup>32</sup>P-labelled<sup>26</sup> AccI/BamHI fragment of the human hPR-56 Pgr cDNA clone which corresponds to the hormone binding and 3'-untranslated domains of the receptor mRNA<sup>7</sup> at 42°C for 16 hours in the presence of dextran sulfate. To control for variability in loading and transfer, blots were stained both before and after transfer with ethidium bromide.

*HindIII POLYMORPHISM*

A representative Southern hybridization analysis of DNA from breast tumors, placentas, and normal lymphocytes digested with *HindIII* and probed with the hPR-56 Pgr cDNA clone is shown in Figure 2. Invariant bands at 9.0, 4.7,

-20-

and 3.6 kb are seen; there are also two polymorphic alleles migrating at about 2.8 and about 2.5-2.6 kb, which are labeled H1 and H2, respectively. Allele frequencies for the *Hind*III polymorphism were determined in a total of 132 breast tumors and 39 placentas (Table 1).

Table 1

| DISTRIBUTION AND FREQUENCIES OF THE PR GENE <i>HIND</i> III RFLP |       |       |       |                              |
|--|-------|-------|-------|------------------------------|
| Genotype (%) <sup>a</sup>  |       |       |       |                              |
| Tissue type  | H1/H1 | H1/H2 | H2/H2 | Frequency of H1 <sup>b</sup> |
| PR+ breast tumors (n=73)   | 67    | 21    | 12    | 0.77 (.71-.84) <sup>c</sup>  |
| PR- breast tumors (n=59)   | 58    | 25    | 17    | 0.70 (.62-.78)               |
| placenta (n=39)  | 54    | 46    | 0     | 0.77 (.67-.86)               |

a  $\chi^2$  analysis was performed to compare allele distribution between PR+ and PR- tumors.

b Calculations for allele frequencies based on the Hardy-Weinberg equation, giving  $p=0.0004$  for PR+,  $0.003$  for PR-, and  $0.06$  for placenta.

c Numbers in parentheses, 95% confidence intervals.

The frequency of the H1 allele in breast tumors was 77% and 70% in PgR-positive and PgR-negative tumors, respectively, and the *Hind*III alleles were not associated with PgR expression levels in these tumors. However, the frequency of the *Hind*III RFLP in tumors did not exhibit a typical Mendelian distribution. The inventors hypothesize whether a genetic selection is occurring which accounts for the observed disequilibrium of these *Hind*III alleles in breast tumors. The placenta DNAs tested contained no detectable H2 homozygotes, although this did not reach statistical significance ( $p = 0.06$ ).

-21-

Thus, a higher incidence of particular abnormalities in the form of characteristic H1 and/or H2 allelic profiles was discovered. Further, by employing the observations disclosed by the inventors, the oncogenesis of aggressive breast cancers may be even more closely examined and identified.

**Example 3**  
**H1 - Allele Free Profile**  
10      **and H2/H2 Allelic Profile as a Breast Cancer**  
         **Genetic Marker**

The present example is provided to demonstrate that the H2 homozygotes or the H1 allele free patient profiles in the breast tumor population may represent a specific loss of the H1 allele as a marker in tumor tissue.

The *HindIII* RFLP was used to determine the presence of breast cancer or the susceptibility to breast cancer in lymphocyte samples. A group of 10 lymphocyte DNAs were examined: The H2 homozygote was not present in this series. These gene frequency differences reflect the three populations selected for analysis. A larger series of lymphocyte samples would determine the incidence and significance of the H2 homozygote in normal tissues.

★★

While the H2/H2 genotype has been reported by others in lymphocyte DNA<sup>1</sup>, this genotype *per se*, or the absence of the H1 genotype, has not been described as part of a method for cancer prediction or susceptibility. Note that the present inventors have found that the H1/H1 or H1/H2 genotype is not a useful predictor for this condition.

Ten breast tumors and adjacent normal breast tissue were examined according to the protocol outlined in Example 2. Five informative normal/tumor pairs heterozygous for the *HindIII* allele were detected, but a loss of the H1 allele in these tumors was not seen.

-22-

Thus, while it appears that not all breast tumors will show an H2/H2 genotype, the H2/H2 genotype has been shown only in individuals having a breast tumor (or at risk). A previous report has detected a loss of heterozygosity at one or more loci on the short arm of chromosome 11<sup>10</sup>. This allele loss was associated with grade III tumors, ER and PgR-negative tumors, and distant metastasis. However, PgR is located distal to this location at 11q21-23<sup>8</sup>.

Polymorphisms were not detected using the restriction enzymes EcoRI and Pvu II in these same 132 tumors. PgR gene amplification (greater than 2-3 fold) was also not detected in any of the specimens using EcoRI, or Pvu II and HindIII. Alterations of 11q have been identified by banding analysis in 8/8 breast cancer cell lines. However, these alterations were highly variable in nature<sup>24</sup>. Others, however, have not found such a high frequency of 11q alterations in breast tumors<sup>9</sup>, which agrees with the results obtained with this group of breast tumors. Major PgR gene rearrangement and amplification does not occur, and probably does not account for the lack of PgR expression in the majority of human breast tumors. These results suggest that based on the frequency, it appears that these reported PgR RFLP's may be useful as markers for linkage analysis.

Prophetic Example 4  
Proposed Method for Predicting Patients at Risk  
of breast cancer with a PCR-generated  
nucleic acid segment

The present example is provided to demonstrate the use of the currently defined location of the RFLP for breast cancer to isolate and prepare smaller subsets of the 1.23 kb probe which recognize the HindIII RFLP. A more narrowly defined, smaller nucleic acid fragment which identified the polymorphism of a patient DNA characteristic of breast cancer or susceptibility to



-23-

breast cancer provides several practical and clinical advantages not provided by the use of a larger nucleic acid segment for DNA analysis among the practical advantages are the economical savings for preparing a smaller nucleic acid segment vs. a larger nucleic acid segment such as in the amount of nucleotides and reagents necessary for synthesis, as well as the time required to prepare, process and verify authenticity of a small verses large nucleic acid fragment. The clinical advantages associated with employing a smaller nucleic acid include a reduced risk of identifying a change in the DNA (of the patient) which perhaps overlaps the region of DNA polymorphism specific for breast cancer susceptibility, as indicative of breast cancer, but which instead reflects either a different clinical pathology, or at the very least, not be indicative of breast cancer or susceptibility thereto (false positive).

A smaller fragment would also be more readily utilizable in routine testing in the clinical laboratory of patient samples for testing for the presence of the RFLP described herein. Thus, the smaller fragment may be employed in a technique for the rapid diagnosing of breast cancer development, prognosis and susceptibility. On a technical level, a smaller diagnostic nucleic acid fragment sequence would facilitate a more sensitive assay for detection of the characteristic polymorphism, as "background" bands would be eliminated.

### 30 Methods

A nucleic acid fragment including a smaller fragment will be prepared as described in Example 1. The labeled form of the oligonucleotide was prepared using the radioisotopic label, <sup>32</sup>P.

35 By way of example, a smaller 0.48 kb nucleic acid fragment to be prepared by PCR is hypothesized.

-24-

Accordingly, this prophetic probe may be prepared by PCR. More specifically, a prophetic synthetic oligonucleotide primer corresponding to nucleotides 2301 to 2320 of the human PgR plus an added EcoRI restriction site (5'-CGGAATTCCTACAAACACGTCAGTGGGC-3') and an antisense primer corresponding to nucleotides 2769 to 2788 plus an added HindIII restriction site (5'-GCAAGCTTAAGAGAAGGGGTTTCACCATC-3') may be used to amplify by polymerase chain reaction (PCR) a 0.48 kb fragment of the 1.23 kb PgR. The PCR-amplified 0.48 kb fragment may then be subcloned into pGEM7zf+ and its sequence confirmed by dideoxysequence analysis.

15                    Prophetic Example 5  
                    Proposed Method for Predicting Patients at  
                    Risk of Breast Cancer Using PCR

20                    The present prophetic example is provided to demonstrate the proposed use of PCR to detect the HindIII RFLP in small sample specimens. With the advent of mammography detection of small breast tumors, the amount of clinical specimen available is sometimes limiting and isolation of genomic DNA and traditional Southern analysis are not always feasible.

25                    The inventors propose to determine the nucleotide sequence of the about 2.8 and the about 2.5-2.6 kb HindIII alleles using techniques currently available for sequence determinations in the laboratory. These sequences can be amplified from small amounts of tissue or isolated genomic DNA using an oligonucleotide primer to the 5' end and an antisense oligonucleotide primer to the 3' end of the 2.8 kb and/or 2.5 kb HindIII allele. The PCR products may then be digested with HindIII or directly run on a standard Southern gel and hybridized with probes recognizing the RFLPs by standard hybridization techniques. This proposed method obviates the requirement for sufficient tissue for genomic DNA

-25-

isolation and will be possible once the sequences of the 2.8 and 2.5 kb *Hind*III RFLPs are delineated.

5           The sequence of the 2.8 and 2.5 kb *Hind*III RFLPs are to be determined, more specifically, by obtaining a frozen normal placental tissue, obtaining genomic DNA therefrom, isolating the 2.8 kb band (H1 allele) or the 2.5 kb band (H2 allele) therefrom, preparing a subgenomic clone containing the 2.8 kb fragment or the 2.5 kb  
10       fragment, and employing the respective subgenomic clone to analyze patient sample DNA for the presence of sequences hybridizable thereto.

15       *Preparation of a Subgenomic Clone having a 2.8 kb fragment (H1 allele) or 2.5 kb fragment (H2 allele) and Sequence Determination thereof*

          The placental tissue will first be analyzed for its allelic profile. A placental tissue DNA which has a  
20       discernable H1/H1 allelic profile will then be selected for use in determining a nucleotide sequence for H1 allele. The 2.8 kb DNA containing the H1 allele will be excised from a mock Southern Blot and the DNA cloned into a pGEM vector. The *Hind*III H1 allele insert will be  
25       identified by hybridization with the 1.23 kb probe, as described in Example 1. Dideoxy sequence analysis of the H1/H1 clones that hybridized with the 1.23 kb probe will then be conducted to determine the nucleotide sequence for H1.

30

          The same procedure will be repeated with the 2.5 kb fragment obtained from placental DNA found to have an H1/H2 allelic profile. Specifically, the 2.5 kb region  
35       will be excised from a Southern Blot of DNA from placental tissue known to have an H1/H2 allelic profile.

          The inventors plan to prepare a separate subgenomic clone library for H1 and H2. More specifically, a

-26-

subgenomic library out of the H2 excised region sequence and of the H1 excised region of the described placental Southern Blot analysis of DNA will be prepared.

5 Subgenomic cloning is to be conducted according to that protocol outlined by Struhl,<sup>32</sup> which reference is specifically incorporated herein by reference for this purpose.

10 The presently proposed method will eliminate the need for tissue amounts sufficient to obtain genomic DNA isolation in a method for analyzing genetic abnormalities in a patient DNA.

BIBLIOGRAPHY

5 The following list represents references cited at various points in the Specification. Particular ones of these references (\*), in pertinent part, are specifically incorporated herein by reference for the purposes herein indicated.

- 10 1. O'Malley BW: The steroid receptor superfamily: More excitement predicted for the future. Mol Endocrinol 4:363-369, 1990
- 15 2. Osborne CK, Yochmowitz MG, Knight WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884-2888, 1980
- 20 3. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS: Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 309:1343-1347, 1983
- 25 4. Jeltsch JM, Krozowski Z, Quirin-Striker C, Gronemeyer H, Simpson RJ, Garnier JM, Krust A, Jacob F, Chambon P: Cloning of the chicken progesterone receptor. Proc Natl Acad Sci USA 83:5424-5428, 1986
- 30 5. Conneely OM, Sullivan WP, Toft DO, Birnbaumer M, Cook RG, Maxwell BL, Zarucki-Schulz T, Greene GL, Schrader WT, O'Malley BW: Molecular cloning of the chicken progesterone receptor. Science 233:767-770, 1986
- 35 6. Loosfelt H, Atger M, Misrahi M, Guiochon-Mantel A, Meriel C, Logeat F, Benarous R, Milgrom E: Cloning and sequence analysis of rabbit progesterone

-28-

receptor complementary DNA. Proc Natl Acad Sci USA  
83:9045-9049, 1986

- 5 7. Misrahi M, Aatger M, d'Auriol L, Loosfelt H, Meriel  
C, Fridlansky F, Guiochon-Mantel A, Galibert F,  
Milgram E: Complete amino acid sequence of the  
human progesterone receptor deduced from cloned  
cDNA. Biochem Biophys Res Commun 143:740-748, 1987
- 10 8. Law ML, Kao FT, Wei Q, Hartz JA, Greene GL, Zarucki-  
Schulz T, Conneely OM, Jones C, Puck TT, O'Malley  
BW, Horwitz KB: The progesterone receptor gene maps  
to human chromosome band 11q13, the site of the  
mammary oncogene int-2. Proc Natl Acad Sci USA  
15 84:2877-2881, 1987
9. Trent JM: Cytogenetic and molecular biologic  
alterations in human breast cancer: A review. Br  
Cancer Res Treat 5:221-229, 1985
- 20 10. Ali IU, Lidereau R, Theillet C, Callahan R:  
Reduction to homozygosity of genes on chromosome 11  
in human breast neoplasia. Science 238:185-238,  
1987
- 25 11. Mackay J, Elder PA, Porteous DJ, Steel CM, Hawkins  
RA, Going JJ, Chetty U: Partial deletion of  
chromosome 11p in breast cancer correlates with size  
of primary tumour and oestrogen receptor level. Br  
30 J Cancer 58:710-714, 1988
12. Theillet C, Lidereau R, Escot C, Hutzell P, Burnet  
M, Gest J, Schlom J, Callahan R: Loss of a c-H-ras-  
1 allele and aggressive human primary breast  
35 carcinomas. Cancer Res 46:4776-4781, 1985

-29-

13. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
- 5 14. Cline MJ, Battifora H, Yokota J: Proto-oncogene abnormalities in human breast cancer: Correlations with anatomic features and clinical course of disease. J Clin Oncol 5:999-1006, 1987
- 10 15. Varley JM, Swallow JE, Brammer WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1:423-430, 1987
- 15 16. Adnane J, Gaudray P, Simon M-P, Simony-Lafontaine J, Jeanteur P, Theillet C: Proto-oncogene amplification and human breast tumor phenotype. Oncogene 4:1389-1395, 1989
- 20 17. Callahan Rk, Campbell G: Mutations in human breast cancer: An overview. J Natl Cancer Inst 81:1780-1786, 1989
- 25 18. Read LD, Snider CE, Miller JS, Greene GL, Katzenellenbogen BS: Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol 2:263-271, 1988
- 30

-30-

19. Wei LL, Krett NL, Francis MD, Gordon DF, Wood WM,  
O'Malley BW, Horwitz KB: Multiple human  
progesterone receptor messenger ribonucleic acids  
and their autoregulation by progestin agonists and  
antagonists in breast cancer cells. Mol Endocrinol  
2:62-72, 1988
- \*20. Southern EM: Detection of specific sequences among  
DNA fragments separated by gel electrophoresis. J  
Mol Biol 98:504-517, 1975
21. Watkins PC: Restriction fragment length  
polymorphism (RFLP): Applications in human  
chromosome mapping and genetic disease research.  
Biotechniques 6:310-319, 1988
22. Cavenee WK, Murphree AL, Shull MM, Benedict WF,  
Sparkes RS, Kock E, Nordenskjold M: Prediction of  
familial predisposition to retinoblastoma. N Engl J  
Med 314:1201-1247, 1986
23. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire  
WL: DNA flow cytometry and prognostic factors in  
1331 frozen breast cancer specimens. Cancer 51:420-  
427, 1988
24. Satya-Prakash KL, Pathak S, Hsu TC, Olive M,  
Cailleau RE: Cytogenetic analysis on eight human  
breast tumor cell lines: high frequencies of 1q.  
11q and HeLa-like marker chromosomes. Cancer Genet  
Cytogenet 3:61-73, 1981
- \*25. Giles KW, Myers A: An improved diphenylamine method  
for the estimation of deoxyribonucleic acid.  
Nature 206:93, 1965



-31-

26. Feinberg AP, Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. *Anal Biochem* 132:6-13, 1983
- 5 27. Huggins et al. (1962) *Science* 137:257-262
28. Huggins et al. (1962) *Proc Natl Acad Sci USA* 48:379-386
- 10 29. Kan et al. (1978) *Proc Natl Acad Sci USA* 75:5631; Gusella et al. (1983) *Nature* 306:234 1983; D.S. Gerhard et al. (1984) *Am J Hum Genet* 36:35; M.J.M. Saraiva et al. (1986) *Neurology* 36:1413; Bartlett et al. (1987) *Science* 235:1648; P.H. St. George-Hyslop et al., *ibid*, 885; M. Barrow et al (1987) *Nature* 326:289; J.M. Rommens et al. (1989) *Science* 245:1059; J.R. Riordan et al., *ibid*, 1066; B. Kerem et al., *ibid*, 1073
- 15 30. Mayslin et al. (1988), *Genomics*, 2:66.
- 20 31. Okayama et al. (1983), *Mol. Cell. Biol.*, 3:280-289.
- 25 32. Struhl, Kevin (1985), *Biotechniques*, 3(6): 452-453.

-32-

## SEQUENCE LISTING

I. General Information:

- i) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF  
TEXAS SYSTEM
- ii) Inventors: MCGUIRE, William L.  
FUQUA, Suzanne A. W.
- iii) Title of Invention: METHODS AND COMPOSITIONS FOR  
THE DETECTION AND PREDICTION  
OF BREAST CANCER
- iv) Number of Sequences: 2
- v) Correspondence Address: Arnold, White & Durkee  
P. O. Box 4433  
Houston, Texas 77027  
USA
- vi) Computer Readable Form: IBM PC-Compatible Floppy  
Disk,  
MS-DOS, WP5.1
- vii) Current Application Data: Appn. No.: Unknown  
Filing Date: Unknown  
Classification:  
Unknown
- viii) Previous Application Data: Appn. No.: 07/743,606  
Filing Date: 08/12/91  
Classification: 435
- ix) Attorney/Agent Information: Denise L. Mayfield  
Reg. No. 33,732  
Ref./Dkt. No. UTFK167PCT
- x) Telecommunication Information: phone:(512)320-7200  
fax: (512) 474-7577

## 2. Information For SEQ ID NO:1:

x) Sequence Characteristics: Length: 1.23 kb  
 Type: nucleic acid  
 Strandedness: single  
 Topology: linear

5

## xi) Sequence Description:

10 Sequence I.D. No. 1:

|    |            |            |             |            |            |             |
|----|------------|------------|-------------|------------|------------|-------------|
| 15 | 10         | 20         | 30          | 40         | 50         | 60          |
|    | GUCUACCCGC | CCUAUCUCA  | CUACCUGAG   | CCGGAUUCAG | AAGCCAGCCA | GAGCCACAA   |
|    | 70         | 80         | 90          | 100        | 110        | 120         |
|    | UACAGCUUCG | AGUCAUUACC | UCAGAAGAUU  | UGUUUAAUCU | GUGGGGAUGA | AGCAUCAGGC  |
|    | 130        | 140        | 150         | 160        | 170        | 180         |
|    | UGUCAUUUG  | GUGUCCUAC  | CUGUGGGAGC  | UGUAAGGUCU | UCUUUAAGAG | GGCA AUGGAA |
| 20 | 190        | 200        | 210         | 220        | 230        | 240         |
|    | GGGCAGCACA | ACUACUUUG  | UGCUGGAAGA  | AAUGACUGCA | UCGUUGAUAA | AAUCCGCAGA  |
| 25 | 250        | 260        | 270         | 280        | 290        | 300         |
|    | AAAAACUGCC | CAGCAUGUCG | CCUUAAGAAAG | UGCUGUCAGG | CUGGCAUGGU | CCUUGGAGGU  |
|    | 310        | 320        | 330         | 340        | 350        | 360         |
|    | CGAAAAUUUA | AAAAGUUCAA | UAAAGUCAGA  | GUUGUGAGAG | CACUGGAUGC | UGUUGCUCUC  |
| 30 | 370        | 380        | 390         | 400        | 410        | 420         |
|    | CCACAGCCAG | UGGGCGUUC  | AAAUGAAAGC  | CAAGCCCUAA | GCCAGAGAUU | CACUUUUUA   |

|    |                     |                    |                     |                    |                    |                        |
|----|---------------------|--------------------|---------------------|--------------------|--------------------|------------------------|
| 5  | 430<br>CAGGUCAAG    | 440<br>ACAUACAGUU  | 450<br>GAUCCACCA    | 460<br>CUGAUCAACC  | 470<br>UGUUAAUGAG  | 480<br>CAUUGAACCA      |
|    | 490<br>GAUGUGAUCU   | 500<br>AUGCAGGACA  | 510<br>UGACAAACACA  | 520<br>AAACCUGACA  | 530<br>CCUCCAGUUC  | 540<br>UUUGCUGACA      |
|    | 550<br>AGUCUUAUUC   | 560<br>AACUAGGCGA  | 570<br>GAGGCAACUU   | 580<br>CUUUCAGUAG  | 590<br>UCAAGUGGUC  | 600<br>UAAAUCAUUG      |
|    | 610<br>CCAGGUUUUC   | 620<br>GAAACUUACA  | 630<br>UAUUGAUGAC   | 640<br>CAGAUAAUCUC | 650<br>UCAUUCAGUA  | 660<br>UUCUUGGAUG      |
|    | 670<br>AGCUUAAUGG   | 680<br>UGUUUGGUCU  | 690<br>AGGAUGGAGA   | 700<br>UCCUACAAAC  | 710<br>ACGUCAGUGG  | 720<br>GCAGAUGCUG      |
| 15 | 730<br>UAUUUUGCAC   | 740<br>CUGAUCUAAU  | 750<br>ACUAAAUGAA   | 760<br>CAGCGGAUGA  | 770<br>AAGAAUCAUC  | 780 13<br>AUUCUAUUCA 4 |
|    | 790<br>UUAUGCCUUA   | 800<br>CCAUGUGGCA  | 810<br>GAUCCACACAG  | 820<br>GAGUUUGUCA  | 830<br>AGCUUCAAGU  | 840<br>UAGCCAAGAA      |
|    | 850<br>GAGUUCCUCU   | 860<br>GUAUGAAAGU  | 870<br>AUUGUUUACUU  | 880<br>CUUAAUACAA  | 890<br>UUCCUUUGGA  | 900<br>AGGGCUACGA      |
|    | 910<br>AGUCAAAACCC  | 920<br>AGUUUGAGGA  | 930<br>GAUGAGGUCA   | 940<br>AGCUACAUAU  | 950<br>GAGAGCUCAU  | 960<br>CAAGGCAAUU      |
|    | 970<br>GGUUUGAGGC   | 980<br>AAAAAGGAGU  | 990<br>UGUGUCGAGC   | 1000<br>UCACAGCGUU | 1010<br>UCUAUCAACU | 1020<br>UACAAAACUU     |
| 30 | 1030<br>CUUGAUAAACU | 1040<br>UGCAUGAUCU | 1050<br>UGUCAAAACAA | 1060<br>CUUCAUCUGU | 1070<br>ACUGCUUGAA | 1080<br>UACAUUUUUC     |

-35-

|            |            |             |            |            |            |
|------------|------------|-------------|------------|------------|------------|
| 1090       | 1100       | 1110        | 1120       | 1130       | 1140       |
| CAGUCCCGGG | CACUGAGUGU | UGAAUUUCCA  | GAAAUGAUGU | CUGAAGUUAU | UGCUGCACAA |
| 1150       | 1160       | 1170        | 1180       | 1190       | 1200       |
| UUACCCAAGA | UAUUGGCAGG | GAUGGUGAAA  | CCCCUUCUCU | UUCAUAAAAA | GUGAAUGUCA |
| 1210       | 1220       | 1230        |            |            |            |
| UCUUUUUCUU | UUAAGAAUU  | AAUUUUGUG G |            |            |            |

5

10

## 2. Information For SEQ ID NO:2:

x) Sequence Characteristics: Length: 0.48 kb  
 Type: nucleic acid  
 Strandedness: single  
 Topology: linear

## xi) Sequence Description:

## 10 Sequence I.D. No. 2:

|    |            |     |            |            |             |            |             |
|----|------------|-----|------------|------------|-------------|------------|-------------|
| 15 | CUACAAACAC | 10  | 20         | 30         | 40          | 50         | 60          |
|    |            |     | GUCAGUGGGC | AGAUGCUGUA | UUUUGCACCU  | GAUCUAAUAC | UAAAUGAACA  |
|    | GCGGAUGAAA | 70  | 80         | 90         | 100         | 110        | 120         |
|    |            |     | GAAUCAUCAU | UCUAUUCAUU | AUGCCUUAAC  | AUGUGGCAGA | UCCCCACAGGA |
|    | GUUUGUCAAG | 130 | 140        | 150        | 160         | 170        | 180         |
|    |            |     | CUUCAAGUUA | GCCAAGAAGA | GUUCCUCUGU  | AUGAAAGUUA | UGUUACUUCU  |
| 20 | UAAUACAAUU | 190 | 200        | 210        | 220         | 230        | 240         |
|    |            |     | CCUUUGGAAG | GGCUACGAAG | UCAAACCCAG  | UUUGAGGAGA | UGAGGUCAAG  |
|    | CUACAUUAGA | 250 | 260        | 270        | 280         | 290        | 300         |
| 25 |            |     | GAGCUCAUCA | AGGCAAUUGG | UUUGAGGCAA  | AAAGGAGUUG | UGUCGAGCUC  |
|    | ACAGCGUUUC | 310 | 320        | 330        | 340         | 350        | 360         |
|    |            |     | UAUCAACUUA | CAAAACUUCU | UGAUAAACUUG | CAUGAUCUUG | UCAAACAACU  |
| 30 | UCAUCUGUAC | 370 | 380        | 390        | 400         | 410        | 420         |
|    |            |     | UGCUUGAAUA | CAUUUAUCCA | GUCCCCGGCA  | CUGAGUGUUG | AAUUUCCAGA  |

-37-

480  
UGGUGAAAACC

470  
UUGGCAGGGA

460  
ACCCAAGAUA

450  
CUGCACAUAU

440  
GAAGUUAUUG

430  
AAUGAUGUCU

488

CCUUCUCU

5

-38-

CLAIMS:

1. A method for diagnosing breast cancer, or  
susceptibility to breast cancer, in a patient, the method  
5 comprising:

obtaining a tissue or blood specimen from a patient;

processing the specimen to obtain DNA;

10 subjecting the DNA to a restriction enzyme capable  
of defining regions of a *HindIII* polymorphism,  
so as to provide DNA restriction fragments;  
and

15 diagnosing a patient homozygous for the H2 allele or  
absent a H1 allele as having breast cancer or  
as being susceptible to breast cancer.

20 2. The method of claim 1 wherein the tissue specimen is  
a breast tissue specimen.

25 3. The method of claim 1, wherein the tissue specimen  
comprises blood cells, buccal smear, skin, breast tissue,  
hair or thymus.

30 4. The method of claim 1, wherein the DNA comprises  
genomic DNA.

35 5. The method of claim 1 wherein the DNA restriction  
fragments are separated by length and probed to locate  
segments of an RFLP therein, said segments of the RFLP



-39-

being hybridizable to a nucleic acid segment having a H1 or H2 allele.

5 6. The method of claim 1 wherein a H1 allele or a H2 allele is located by probing the isolated DNA restriction fragments with a nucleic acid probe having a sequence defined in figure 1 or a fragment thereof.

10 7. The method of claim 1 wherein the H1 allele or the H2 allele is located with a nucleic acid probe having a sequence defined in figure 2 or a fragment thereof.

15 8. The method of claim 1 wherein the DNA restriction fragments are separated by electrophoresis.

20 9. The method of claim 1 wherein the restriction enzyme is other than EcoRI, or Pvu II.

25 10. The method of claim 1 wherein the restriction enzyme is HindIII restriction enzyme.

30 11. The method of claim 1 wherein the H1 allele is within a DNA restriction fragment having a length of about 2.8 kb.

35 12. The method of claim 1 wherein the H2 allele is within a DNA restriction fragment having a length of about 2.6 kb.

-40-

13. The method of claim 1 wherein the H1 allele or the H2 allele is located with a 0.48 kb nucleic acid fragment of the sequence defined in Figure 1.

5

14. The method of claim 1 wherein the presence of an H2 allele or an H1 allele is identified using a nucleic acid probe having a sequence defined in Figure 1, or a fragment thereof.

10

15. The method of claim 1 wherein the presence of an H2 allele or an H1 allele is identified with a nucleic acid probe having a sequence defined in Figure 2, or a fragment thereof.

15

16. The method of claim 15 wherein the nucleic acid probe is defined as a labeled 1.23 kb *AccI*/*BamHI* DNA fragment of a *PgR* nucleic acid sequence.

20

17. A method of detecting a *HindIII* RFLP in a DNA sample, wherein said *HindIII* RFLP identifies a polymorphism characteristic of breast cancer or susceptibility thereto, comprising:

25

treating the DNA sample with a restriction enzyme capable of producing a DNA restriction fragment having a *HindIII* polymorphism, to produce DNA restriction fragments;

30

probing the DNA restriction fragments with a nucleic acid segment capable of identifying a *HindIII* RFLP; and

35

-41-

identifying a *HindIII* RFLP in a segment of the separated DNA restriction fragment which hybridizes with the nucleic acid segment or a fragment thereof.

5

18. The method of claim 17 wherein the polymorphism for breast cancer or susceptibility to breast cancer is the absence of an H1 allele.

10

19. The method of claim 17 wherein the polymorphism for breast cancer or susceptibility to breast cancer is a H2/H2 allelic profile.

15

20. A nucleic acid segment suitable for use as a probe and capable of identifying a *HindIII* RFLP characteristic of human breast cancer or susceptibility thereto.

20

21. The nucleic acid segment of claim 20 wherein the RFLP identifies an H2/H2 gene allelic condition or the absence of an H1 gene allele.

25

22. The nucleic acid segment of claim 20 having a sequence defined in Figure 1 or a fragment thereof.

30

23. The nucleic acid segment of claim 20 having a sequence defined in figure 2 or a fragment thereof.

35

24. A method for diagnosing breast cancer, or susceptibility to breast cancer in a patient, the method comprising:

-42-

obtaining a tissue or blood specimen from a patient;

processing the specimen to obtain DNA;

5        analyzing DNA for the presence of a nucleic acid  
         sequence hybridizable to a nucleic acid  
         segment defined at Figure 1;

         and diagnosing breast cancer or susceptibility  
10       thereto in a patient whose DNA hybridizes to  
         the nucleic acid sequence defined at Figure 1,  
         or a fragment thereof.

15       25. A kit for the prediction of breast cancer or breast  
         cancer susceptibility in a patient, the kit comprising a  
         hybridization probe capable of hybridizing to an H1 and  
         H2 RFLP, wherein the probe is comprised in a suitable  
         container.

20

         26. The kit of claim 25, further comprising means for  
         packaging said container.

25

         27. The kit of claim 25, wherein the probe comprises a  
         DNA segment.

30       28. The kit of claim 25, wherein the nucleic acid probe  
         comprises a segment of about 1.23 kb or less.

         29. The kit of claim 28, wherein the nucleic acid probe  
35       comprises the sequence of figure 1, or a fragment  
         comprising a hybridizable portion of the sequence.

-43-

30. The kit of claim 28, wherein the nucleic acid probe comprises the sequence of figure 2.

5 31. The kit of claim 25, further comprising means for detecting hybridization between the probe and an H1 or H2 RFLP.

10 32. The kit of claim 31, wherein the detecting means comprises a label on the probe.

15 33. The kit of claim 32, wherein the label comprises an enzyme or radioactive label.

10 20 30 40 50 60  
GUCUACCCGC CCUAUCUCAA CUACCUGAGG CCGGAUUCAG AAGCCAGCCA GAGCCACAA  
70 80 90 100 110 120  
UACAGCUUCG AGUCAUUACC UCAGAAGAUU UGUUUAAUCU GUGGGGAUGA AGCAUCAGGC  
130 140 150 160 170 180  
UGUCAUUAUG GUGUCCUAC CUGUGGGAGC UGUAAAGGUCU UCUUUAAGAG GGCAAUGGAA  
190 200 210 220 230 240  
GGGCAGCACA ACUACUUAUG UGCUGGAAGA AAUGACUGCA UCGUUGAUAA AAUCCGCAGA  
250 260 270 280 290 300  
AAAAACUGCC CAGCAUGUCG CCUAGAAAG UGCUGUCAGG CUGGCAUGGU CCUUGGAGGU  
310 320 330 340 350 360  
CGAAAAUUUA AAAAGUUCAA UAAAGUCAGA GUUGUGAGAG CACUGGAUCG UGUUGCUCUC

1/7

FIG. 1A

SUBSTITUTE SHEET

2/7

370            380            390            400            410            420  
CCACAGCCAG UGGGCGUUC AAAUGAAAGC CAAGCCCUAA GCCAGAGAUU CACUUUUUCA  
430            440            450            460            470            480  
CCAGGUCAAG ACAUACAGUU GAUCCACCA CUGAUCAACC UGUUAAUGAG CAUGAACCA  
490            500            510            520            530            540  
GAUGUGAUCU AUGCAGGACA UGACAAACACA AAACCUGACA CCUCCAGUUC UUUGCUGACA  
550            560            570            580            590            600  
AGUCUUAAUC AACUAGGCGA GAGGCAACUU CUUUCAGUAG UCAAGUGGUC UAAAUCAUUG  
610            620            630            640            650            660  
CCAGGUUUUC GAAACUUACA UAUUGAUGAC CAGAUAAACUC UCAUUCAGUA UUCUUGGAUG  
670            680            690            700            710            720  
AGCUUAAUGG UGUUUGGUCU AGGAUGGAGA UCCUACAAAC ACGUCAGUGG GCAGAUGCUG

FIG. 1B

SUBSTITUTE SHEET

3/7

|             |            |             |            |            |            |
|-------------|------------|-------------|------------|------------|------------|
| 730         | 740        | 750         | 760        | 770        | 780        |
| U AUUUUGCAC | CUGAUCUAAU | ACUAAAUGAA  | CAGCGGAUGA | AAGAAUCAUC | AUUCUAUUA  |
| 790         | 800        | 810         | 820        | 830        | 840        |
| UUAUGCCUUA  | CCAUGUGGCA | GAUCCACACAG | GAGUUUGUCA | AGCUUCAAGU | UAGCCAAGAA |
| 850         | 860        | 870         | 880        | 890        | 900        |
| GAGUCCUCU   | GUAUGAAAGU | AUUGUUACUU  | CUAAAUACAA | UUCCUUUGGA | AGGGCUACGA |
| 910         | 920        | 930         | 940        | 950        | 960        |
| AGUCAAAACC  | AGUUUGAGGA | GAUGAGGUCA  | AGCUACAUA  | GAGAGCUCAU | CAAGGCAAUU |
| 970         | 980        | 990         | 1000       | 1010       | 1020       |
| GGUUUGAGGC  | AAAAGGAGU  | UGUGUCGAGC  | UCACAGCGUU | UCUAUCAACU | UACAAAACUU |

FIG. 1C

SUBSTITUTE SHEET



4/7

|             |            |            |            |            |             |
|-------------|------------|------------|------------|------------|-------------|
| 1030        | 1040       | 1050       | 1060       | 1070       | 1080        |
| CUUGAUAAACU | UGCAUGAUCU | UGUCAAACAA | CUUCAUCUGU | ACUGCUUGAA | UACAUUUUAUC |
| 1090        | 1100       | 1110       | 1120       | 1130       | 1140        |
| CAGUCCCGGG  | CACUGAGUGU | UGAAUUUCCA | GAAUGAUGU  | CUGAAGUUAU | UGCUGCACAA  |
| 1150        | 1160       | 1170       | 1180       | 1190       | 1200        |
| UUACCCAAGA  | UAUUGGCAGG | GAUGGUGAAA | CCCCUUCUCU | UUCAUAAAAA | GUGAAUGUCA  |
| 1210        | 1220       | 1230       |            |            |             |
| UCUUUUUCUU  | UUAAAGAAUU | AAAUUUUGUG | G          |            |             |

SUBSTITUTE SHEET

FIG. 1D

5/7

|            |            |             |             |             |            |
|------------|------------|-------------|-------------|-------------|------------|
| 10         | 20         | 30          | 40          | 50          | 60         |
| CUACAAACAC | GUAGUGGGC  | AGAUGCUGUA  | UUUUGCACCU  | GAUCUAAUAC  | UAAAUGAACA |
| 70         | 80         | 90          | 100         | 110         | 120        |
| GCGGAUGAAA | GAAUCAUCAU | UCUAUUCAUU  | AUGCCUUACC  | AUGUGGCAGA  | UCCCACAGGA |
| 130        | 140        | 150         | 160         | 170         | 180        |
| GUUUGUCAAG | CUUCAAGUUA | GCCAAAGAAGA | GUUCCUCUGU  | AUGAAAGUUAU | UGUUACUUCU |
| 190        | 200        | 210         | 220         | 230         | 240        |
| UAAUACAAUU | CCUUUGGAAG | GGCUACGAAG  | UCAAACCCAG  | UUUGAGGAGA  | UGAGGUCAAG |
| 250        | 260        | 270         | 280         | 290         | 300        |
| CUACAUUAGA | GAGCUCAUCA | AGGCAAUUGG  | UUUGAGGCCAA | AAAGGAGUUG  | UGUCGAGCUC |
| 310        | 320        | 330         | 340         | 350         | 360        |
| ACAGCGUUUC | UAUCAACUUA | CAAAACUUCU  | UGAUAAACUUG | CAUGAUCUUG  | UCAAACAACU |

FIG. 2A

SUBSTITUTE SHEET

6/7

|            |            |            |            |            |            |
|------------|------------|------------|------------|------------|------------|
| 370        | 380        | 390        | 400        | 410        | 420        |
| UCAUCUGUAC | UGCUGGAAUA | CAUUUAUCCA | GUCCCGGGCA | CUGAGUGUUG | AAUUUCCAGA |
| 430        | 440        | 450        | 460        | 470        | 480        |
| AAUGAUGUCU | GAAGUUAUUG | CUGCACAAUU | ACCCAAGAUU | UUGGCAGGGA | UGGUGAAACC |
| 490        | 500        | 510        | 520        | 530        |            |
| CCUUCUCUUU | CAUAAAAAGU | GAAUGUCAUC | UUUUUCUUUU | AAAGAAUUA  | AUUUUGUGG  |

FIG. 2B

SUBSTITUTE SHEET

7/7




FIG. 3

## INTERNATIONAL SEARCH REPORT

PCT/US 92/06701

International Application No

|  |  |                                     |
|--|--|-------------------------------------|
| I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) <sup>6</sup>   |  |                                     |
| According to International Patent Classification (IPC) or to both National Classification and IPC  |  |                                     |
| Int.Cl. 5 C12Q1/68   |  |                                     |
| II. FIELDS SEARCHED  |  |                                     |
| Minimum Documentation Searched <sup>7</sup>  |  |                                     |
| Classification Systems   | Classification Symbols   |                                     |
| Int.Cl. 5  | C12Q   |                                     |
| Documentation Searched other than Minimum Documentation<br>to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>  |  |                                     |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup>  |  |                                     |
| Category <sup>10</sup>   | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>   | Relevant to Claim No. <sup>13</sup> |
| X  | SCIENCE<br>vol. 238, 9 October 1987, LANCASTER, PA US<br>pages 185 - 188<br>I.U. ALI ET AL. 'Reduction to homozygosity<br>of genes on chromosome 11 in human breast<br>neoplasia'<br>cited in the application<br>see the whole document, especially the<br>abstract, fig. 1 and table 1<br>---<br>-/-- | 1,10                                |
| <sup>10</sup> Special categories of cited documents:<br>"A" document defining the general state of the art which is not<br>considered to be of particular relevance<br>"E" earlier document but published on or after the international<br>filing date<br>"L" document which may throw doubts on priority claim(s) or<br>which is cited to establish the publication date of another<br>citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or<br>other means<br>"P" document published prior to the international filing date but<br>later than the priority date claimed<br>"T" later document published after the international filing date<br>or priority date and not in conflict with the application but<br>cited to understand the principle or theory underlying the<br>invention<br>"X" document of particular relevance; the claimed invention<br>cannot be considered novel or cannot be considered to<br>involve an inventive step<br>"Y" document of particular relevance; the claimed invention<br>cannot be considered to involve an inventive step when the<br>document is combined with one or more other such docu-<br>ments, such combination being obvious to a person skilled<br>in the art.<br>"A" document member of the same patent family |  |                                     |
| IV. CERTIFICATION  |  |                                     |
| Date of the Actual Completion of the International Search  | Date of Mailing of this International Search Report  |                                     |
| 04 NOVEMBER 1992   | 23.11.92   |                                     |
| International Searching Authority  | Signature of Authorized Officer  |                                     |
| EUROPEAN PATENT OFFICE   | LUZZATTO E.R.  |                                     |

| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) |   |                       |
|--|---|-----------------------|
| Category *   | Citation of Document, with indication, where appropriate, of the relevant passages  | Relevant to Claim No. |
| X  | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.<br>vol. 143, no. 2, 1987, DULUTH, MINNESOTA US<br>pages 740 - 748<br>MISRAHI M. ET AL. 'Complete amino acid sequence of the human progesterone receptor deduced from cloned DNA'<br>cited in the application<br>see the whole document, especially the abstract<br>--- | 20-24                 |
| X  | CANCER RESEARCH<br>vol. 48, no. 14, July 1988,<br>PHILADELPHIA, USA<br>pages 4045 - 4048<br>J.S. LEE ET AL. 'Multiple restriction fragment length polymorphism of the human epidermal growth factor receptor gene'<br>see abstract<br>see "Discussion"<br>----  | 1,10                  |
| A  | SURGICAL FORUM<br>vol. 38, 1987, CHICAGO, USA<br>pages 402 - 405<br>A.-M. MARCOUX ET AL. 'Restriction fragment length polymorphisms of type I collagen as genetic markers for breast cancer'<br>see the whole document<br>----  | 1,9                   |
| A  | BREAST CANCER RESEARCH AND TREATMENT<br>vol. 14, no. 1, 1989, THE HAGUE, THE NETHERLANDS<br>pages 57 - 64<br>F.F. PARL ET AL. 'Genomic DNA analysis of the estrogen receptor gene in breast cancer'<br>see abstract<br>----   | 1,9                   |
| A  | FR,A,2 628 441 (IMPERIAL CHEMICAL INDUSTRIES)<br>15 September 1989<br>see page 2, line 6 - page 3, line 25;<br>claims<br>-----  | 1                     |

US 9206701  
SA 63706

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 04/11/92

EPO FORM 10479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82